Page last updated: 2024-10-27

fluorouracil and Biliary Tract Cancer

fluorouracil has been researched along with Biliary Tract Cancer in 146 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin."9.41A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. ( Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ, 2021)
"We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy."9.20Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. ( Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH, 2015)
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects."9.17Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013)
"The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors."9.16Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012)
"This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients."9.16A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. ( Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V, 2012)
"Many clinical trials have been conducted with gemcitabine- or 5-fluorouracil-based regimens as treatment for unresectable biliary tract cancer; however, the results remain unsatisfactory."9.16A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M, 2012)
"We conducted this phase II study in an effort to evaluate the efficacy and safety of a gemcitabine single chemotherapy as a second-line treatment for biliary tract cancer (BTC) patients who evidenced disease progression after the administration of 5-fluorouracil (5-FU)-based palliative chemotherapy."9.15Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. ( Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2011)
"In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer."9.14Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010)
"Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer."9.14Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009)
"To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer."9.13Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008)
"This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas."9.13Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008)
"The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer."9.12Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007)
"In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57."9.10Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003)
"We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas."9.10Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002)
"Gemcitabine-cisplatin (GP) has been regarded as standard first-line chemotherapy for advanced biliary tract cancer (BTC)."9.05Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis. ( Jin, J; Zhang, Y; Zheng, T; Zhou, L, 2020)
"In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019."7.96First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020)
"The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer."7.81Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015)
"The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy."7.81Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015)
"Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)."7.79Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013)
"The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer."7.79Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013)
"To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy."7.76Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. ( Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S, 2010)
"The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy."7.75Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009)
"Despite the frequent clinical use of 5-fluorouracil (5-FU) in combination with radiotherapy for patients with biliary tract cancers, data remain scarce concerning specifically the influence of 5-FU on the sensitivity of these cancer cells to radiation."7.70Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines. ( Fukao, K; Little, JB; Moon, Y; Ohno, T; Todoroki, T, 2000)
"We describe a patient with an intrahepatic biliary hamartoma associated with transformation to undifferentiated carcinoma which responded to intrahepatic arterial floxuridine chemotherapy."7.70A cystic biliary tumour responding to regional fluorinated pyrimidine infusion. ( Allen-Mersh, TG; Burke, D; Hedayati, B; Shousha, S, 1998)
"The development of pellagra in a patient treated with 5-fluorouracil for malignant disease is reported."7.68Pellagra secondary to 5-fluorouracil. ( Begent, RH; Dooley, JS; Ostlere, LS; Rustin, MH; Stevens, HP, 1993)
"The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial."6.82The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022)
"All patients had pancreatic or biliary tract cancer."6.78A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. ( Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM, 2013)
"Capecitabine was administered at a dose of 1,000 mg/m(2) b."6.74Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009)
" The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer."6.71Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004)
"Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7."6.69Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000)
"In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin."5.41A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. ( Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ, 2021)
"Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period."5.38Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012)
"No standard treatment is available for advanced biliary tract cancer (BTC) after first-line therapy with gemcitabine plus cisplatin (GEMCIS)."5.34Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. ( Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW, 2020)
"Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy."5.32Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? ( Caca, K; Deininger, M; Feisthammel, J; Kreth, F; Mössner, J; Wiedmann, M, 2003)
"Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle."5.27A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018)
"We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy."5.20Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. ( Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH, 2015)
"Inoperable biliary tract cancer patients were treated with the combination of gemcitabine (1000 mg/m(2) on day 1 and 8), capecitabine (1300 mg/m(2)/d on day 1-14) and weekly cetuximab (400mg/m(2) loading and 250 mg/m(2) maintenance dose) in 21-d cycles until progression or the appearance of intolerable side-effects."5.17Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. ( Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z, 2013)
"This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients."5.16A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. ( Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V, 2012)
"The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors."5.16Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. ( Bang, YJ; Han, SW; Im, SA; Kim, TY; Lim, KH; Oh, DY, 2012)
"Many clinical trials have been conducted with gemcitabine- or 5-fluorouracil-based regimens as treatment for unresectable biliary tract cancer; however, the results remain unsatisfactory."5.16A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer. ( Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M, 2012)
"This multisite study sought to optimize the dosing, schedule, and administration of fixed-dose rate (FDR) gemcitabine plus capecitabine for advanced pancreatic and biliary tract cancers using an alternating-week dose schedule of both agents."5.16Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. ( Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP, 2012)
"We conducted this phase II study in an effort to evaluate the efficacy and safety of a gemcitabine single chemotherapy as a second-line treatment for biliary tract cancer (BTC) patients who evidenced disease progression after the administration of 5-fluorouracil (5-FU)-based palliative chemotherapy."5.15Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. ( Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2011)
"The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown."5.14An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010)
"In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer."5.14Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010)
"Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer."5.14Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009)
"To evaluate the effects of palliative chemotherapy with gemcitabine plus capecitabine (GemCap) on patient-reported outcomes measured using clinical benefit response (CBR) and quality-of-life (QOL) measures in patients with advanced biliary tract cancer."5.13Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. ( Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F, 2008)
"This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas."5.13Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008)
"The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer."5.12Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007)
" The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)."5.11Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005)
"Previous small phase II trials have demonstrated that the combination of 5-fluorouracil (5FU) and cisplatin(CDDP) could have clinical activity in metastatic biliary tract cancer."5.11A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. ( Anak, O; Baron, B; Ducreux, M; Gress, TM; Jeziorski, K; Nordlinger, B; Rougier, P; Van Cutsem, E; Van Laethem, JL; Wagener, T, 2005)
"We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas."5.10Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002)
"In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57."5.10Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003)
"We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)."5.09Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001)
"Gemcitabine-cisplatin (GP) has been regarded as standard first-line chemotherapy for advanced biliary tract cancer (BTC)."5.05Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis. ( Jin, J; Zhang, Y; Zheng, T; Zhou, L, 2020)
"Major adjuvant therapies for biliary tract cancer (BTC) include fluorouracil, gemcitabine and chemoradiation (CRT), but the optimum regimen remains inconclusive."4.90Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. ( Braddock, M; Chen, YP; Lin, YQ; Shi, KQ; Wang, LR; You, J; Zheng, MH; Zhu, GQ; Zou, H, 2014)
"In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019."3.96First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020)
"The aim of this retrospective study was to investigate the relationship between UGT1A1 polymorphisms and toxicities in Chinese patients with pancreatic or biliary tract cancer receiving irinotecan-containing regimens as the second- or third-line chemotherapy."3.81Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. ( Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG, 2015)
"The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer."3.81Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015)
"Gemcitabine/capecitabine can be given at the standard dose in patients with severe hyperbilirubinemia, though the present data suggest that gemcitabine's activity may be limited due to poor intracellular activation."3.80Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. ( Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH, 2014)
"The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer."3.79Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013)
"Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)."3.79Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013)
"To investigate in vitro treatment with NVP-AEW541, a small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R), in biliary tract cancer (BTC), since this disease is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy."3.76Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. ( Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S, 2010)
"The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy."3.75Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009)
"We describe a patient with an intrahepatic biliary hamartoma associated with transformation to undifferentiated carcinoma which responded to intrahepatic arterial floxuridine chemotherapy."3.70A cystic biliary tumour responding to regional fluorinated pyrimidine infusion. ( Allen-Mersh, TG; Burke, D; Hedayati, B; Shousha, S, 1998)
"Despite the frequent clinical use of 5-fluorouracil (5-FU) in combination with radiotherapy for patients with biliary tract cancers, data remain scarce concerning specifically the influence of 5-FU on the sensitivity of these cancer cells to radiation."3.70Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines. ( Fukao, K; Little, JB; Moon, Y; Ohno, T; Todoroki, T, 2000)
"The development of pellagra in a patient treated with 5-fluorouracil for malignant disease is reported."3.68Pellagra secondary to 5-fluorouracil. ( Begent, RH; Dooley, JS; Ostlere, LS; Rustin, MH; Stevens, HP, 1993)
"A phase II trial of the regimen 5-fluorouracil, doxorubicin, and mitomycin C (FAM) was conducted in 17 patients with advanced or recurrent biliary tract cancer."3.675-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. ( Harvey, JH; Schein, PS; Smith, FP, 1984)
"The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial."2.82The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022)
"All patients had pancreatic or biliary tract cancer."2.78A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. ( Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM, 2013)
"Capecitabine was administered at a dose of 1,000 mg/m(2) b."2.74Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009)
" Oxaliplatin in combination with leucovorin and 5-FU should be considered a feasible chemotherapy regimen for patients with recurrent/metastatic biliary tract carcinoma."2.73Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. ( Cho, JY; Jeung, HC; Lee, DK; Lee, SJ; Lim, JY; Mun, HS; Paik, YH; Yoon, DS, 2008)
"Cholangiocarcinoma is a rare malignancy with a poor prognosis."2.72Biliary cancer: gateway to comprehensive molecular profiling. ( Sardar, M; Shroff, RT, 2021)
"Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase (DPD)."2.72A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. ( Cohen, DP; Czito, BG; Fernando, N; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Morse, MA; Pappas, TN; Petros, WP; Tyler, DS; Yu, D, 2006)
" Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m2 and cisplatin 60 mg/m2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m2/day, from day 1 to day 14, every 3 weeks."2.71Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study. ( Cantore, M; Carlone, N; Caudana, R; Fiorentini, G; Mambrini, A; Manni, A; Rabbi, C; Torri, T; Zamagni, D, 2003)
" The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer."2.71Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004)
"Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7."2.69Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000)
"2 of the 7 (29%) patients with hepatoma responded."2.68Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. ( Cunningham, D; Ellis, PA; Hickish, T; Hill, A; Nicolson, M; Norman, A; O'Brien, ME, 1995)
"The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder."2.55[Chemotherapy for Biliary Tract Cancer]. ( Woo, SM, 2017)
"Most patients with unresectable biliary tract cancer develop obstructive jaundice, and biliary drainage is needed before any of the aforementioned treatments."2.48Role of chemotherapy in treatments for biliary tract cancer. ( Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A, 2012)
"The prognosis of patients with biliary tract cancer remains unsatisfactory even with surgery owing to the high recurrence rate."2.48Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. ( Konishi, M, 2012)
"Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity."2.44[Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007)
"The incidence of biliary tract cancer has increased markedly in Japan over the past several decades and ranks as the sixth leading cause of cancer death."2.41Chemotherapy for biliary tract cancer in Japan. ( Okusaka, T, 2002)
"5-Fluorouracil has long been the mainstay of the treatment of pancreatic cancer, although the response rate to this agent is < 10% and the influence on survival and quality of life is negligible."2.40Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. ( van Groeningen, CJ, 1999)
"Capecitabine was the most common second-line chemotherapy treatment."1.91Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. ( Abadi, S; Davies, JM; Ho, C; Mathers, B; McIntyre, C, 2023)
"Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies."1.62SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). ( Carrato, A; Feliu, J; Garcia-Carbonero, R; Gómez-España, MA; Martín, AM; Maurel, J; Mercadé, TM; Montes, AF; Pazo-Cid, R; Vera, R, 2021)
"Historically, biliary tract cancer (BTC) and pancreatic cancer have been treated similarly with gemcitabine alone or combined with a platinum compound."1.56A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. ( Almohamad, W; Biondani, P; Chebib, A; Ciacio, O; Gumus, Y; Haydar, M; Innominato, PF; Karaboué, A; Pittau, G; Ulusakarya, A, 2020)
"Biliary tract cancers are rare, and surgical resection is the standard treatment at early stages."1.40Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO). ( Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU, 2014)
"The prognosis of unresectable biliary tract cancer has improved recently."1.39Improvement of prognosis for unresectable biliary tract cancer. ( Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N, 2013)
"Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period."1.38Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012)
"Patients with cholangiocarcinoma or gallbladder cancer have poor overall prognosis and their management is often complex."1.36Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. ( Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T, 2010)
"Twenty-nine patients with pancreatic cancer (PC) and 43 with biliary tract cancer (BTC; 27 cases of bile duct cancer, 8 of gallbladder cancer and 8 of cancer of the papillary area) were included."1.35Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. ( Kubota, K; Sawada, T; Shimoda, M, 2009)
"The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)."1.33Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005)
"Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy."1.32Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? ( Caca, K; Deininger, M; Feisthammel, J; Kreth, F; Mössner, J; Wiedmann, M, 2003)
"Nine of these 18 patients had bile duct cancer, seven had gallbladder cancer, and two had cancer of the papilla of Vater."1.32[Adjuvant arterial infusion chemotherapy for patients with biliary cancer]. ( Hasuike, Y; Kashiwazaki, M; Takeda, Y; Tsujinaka, T, 2004)
"These included 7 cases of pancreatic cancer, 2 cases of gall bladder cancer with infiltration to the liver, and 3 cases of hepatoma."1.27[Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas]. ( Hasegawa, H; Takada, T; Uchiyama, K; Yasuda, H, 1985)

Research

Studies (146)

TimeframeStudies, this research(%)All Research%
pre-19907 (4.79)18.7374
1990's24 (16.44)18.2507
2000's57 (39.04)29.6817
2010's41 (28.08)24.3611
2020's17 (11.64)2.80

Authors

AuthorsStudies
Phelip, JM1
Desrame, J1
Edeline, J1
Barbier, E1
Terrebonne, E1
Michel, P2
Perrier, H1
Dahan, L1
Bourgeois, V1
Akouz, FK1
Soularue, E1
Ly, VL1
Molin, Y1
Lecomte, T2
Ghiringhelli, F1
Coriat, R1
Louafi, S1
Neuzillet, C1
Manfredi, S1
Malka, D1
Rizzo, A1
Ricci, AD1
Brandi, G1
Yoo, C2
Cosgrove, DP1
Reese, ES1
Fulcher, NM1
Bobiak, SS1
Lamy, FX1
Allignol, A1
Boyd, M1
Mahmoudpour, SH1
Mathers, B1
Abadi, S1
Davies, JM1
McIntyre, C1
Ho, C1
Belkouz, A1
de Vos-Geelen, J1
Mathôt, RAA1
Eskens, FALM1
van Gulik, TM1
van Oijen, MGH1
Punt, CJA1
Wilmink, JW1
Klümpen, HJ1
Kim, RD1
McDonough, S1
El-Khoueiry, AB1
Bekaii-Saab, TS1
Stein, SM1
Sahai, V1
Keogh, GP1
Kim, EJ2
Baron, AD1
Siegel, AB1
Barzi, A1
Guthrie, KA1
Javle, M1
Hochster, H1
Sinn, M3
Wege, H1
Stein, A1
Ma, WJ1
Jin, YW1
Wu, ZR1
Yang, Q1
Wang, JK1
Liu, F1
Shi, YJ1
Li, QS1
Cheng, NS1
Ulusakarya, A1
Karaboué, A1
Ciacio, O1
Pittau, G1
Haydar, M1
Biondani, P1
Gumus, Y1
Chebib, A1
Almohamad, W1
Innominato, PF1
Taghizadeh, H1
Unseld, M1
Schmiderer, A1
Djanani, A1
Wilthoner, K1
Buchinger, D1
Prager, GW1
Zheng, T1
Jin, J1
Zhou, L1
Zhang, Y1
Dee, EC1
Freret, ME1
Horick, N1
Raldow, AC1
Goyal, L1
Zhu, AX2
Parikh, AR1
Ryan, DP1
Clark, JW1
Allen, JN1
Ferrone, CR1
Fernandez-Del Castillo, C1
Tanabe, KK1
Drapek, LC1
Hong, TS1
Qadan, M1
Wo, JY1
Sardar, M1
Shroff, RT1
Gómez-España, MA1
Montes, AF1
Garcia-Carbonero, R1
Mercadé, TM1
Maurel, J1
Martín, AM1
Pazo-Cid, R1
Vera, R1
Carrato, A1
Feliu, J1
Choi, IS1
Kim, KH1
Lee, JH3
Suh, KJ1
Kim, JW2
Park, JH1
Kim, YJ1
Kim, JS3
Kim, JH2
Song, S1
Yang, W1
Tian, H1
Gong, S1
Lei, C1
Lv, K1
Lu, T1
Cheng, Q1
Yang, K1
Guo, T1
Woo, SM3
Il Yu, J1
Chul Park, H1
Hoon Lim, D1
Oh Park, J1
Suk Park, Y1
Tae Kim, S1
Ho Choi, S1
Wook Choi, D1
Woong Han, I1
Seok Heo, J1
Kaavya, J1
Mahalaxmi, I1
Devi, SM1
Santhy, KS1
Balachandar, V1
Nicolaou, A1
Gebauer, B1
Podrabsky, P1
Seehofer, D1
Ricke, J1
Dörken, B1
Riess, H2
Hildebrandt, B1
Moretto, R1
Raimondo, L1
De Stefano, A1
Cella, CA1
Matano, E1
De Placido, S1
Carlomagno, C1
Rubovszky, G1
Láng, I1
Ganofszky, E1
Horváth, Z1
Juhos, E1
Nagy, T1
Szabó, E1
Szentirmay, Z1
Budai, B1
Hitre, E1
Kaira, K1
Sunose, Y1
Ohshima, Y1
Ishioka, NS1
Arakawa, K1
Ogawa, T1
Sunaga, N1
Shimizu, K1
Tominaga, H1
Oriuchi, N1
Itoh, H1
Nagamori, S1
Kanai, Y1
Yamaguchi, A2
Segawa, A1
Ide, M1
Mori, M1
Oyama, T1
Takeyoshi, I1
Joerger, M1
Huitema, AD1
Koeberle, D2
Rosing, H1
Beijnen, JH1
Hitz, F1
Cerny, T1
Schellens, JH1
Gillessen, S1
Unal, OU2
Oztop, I2
Unek, IT1
Yilmaz, AU2
Yi, SW1
Kang, DR1
Kim, KS1
Park, MS2
Seong, J1
Park, JY1
Bang, SM2
Song, SY2
Chung, JB2
Park, SW1
Lee, WJ2
Kim, DH1
Han, SS2
Park, SJ3
Kim, TH3
Koh, YH2
Hong, EK2
Adhikaree, J1
Madhusudan, S1
Zhu, GQ1
Shi, KQ1
You, J1
Zou, H1
Lin, YQ1
Wang, LR1
Braddock, M1
Chen, YP1
Zheng, MH1
Kos, T1
Turan, N1
Kucukoner, M1
Helvaci, K1
Berk, V1
Sevinc, A1
Yildiz, R1
Cinkir, Hy1
Tonyali, O1
Demirci, U1
Aktas, B1
Balakan, O1
Hwang, IG3
Jang, JS2
Oh, SY3
Rho, MH2
Lee, S2
Park, YS2
Park, JO2
Nam, EM1
Lee, HR1
Jun, HJ1
Chi, KC1
Russolillo, N1
Ratti, F1
Viganò, L1
Langella, S1
Cipriani, F1
Aldrighetti, L2
Ferrero, A1
Petrioli, R1
Roviello, G1
Fiaschi, AI1
Laera, L1
Roviello, F1
Marrelli, D1
Francini, E1
Yang, C1
Liu, Y1
Xi, WQ1
Zhou, CF1
Jiang, JL1
Ma, T1
Ye, ZB1
Zhang, J1
Zhu, ZG1
Davis, EJ1
Griffith, KA1
Ruch, JM1
McDonnell, KJ1
Zalupski, MM1
Kim, BJ1
Kim, KP1
Hyung, J1
Ryoo, BY1
Chang, HM1
Lim, JY1
Jeung, HC1
Mun, HS1
Lee, DK2
Paik, YH2
Lee, SJ2
Yoon, DS2
Cho, JY2
Tan, BR1
Brenner, WS1
Picus, J1
Marsh, S1
Gao, F1
Fournier, C1
Fracasso, PM1
James, J1
Yen-Revollo, JL1
McLeod, HL1
Saletti, P1
Borner, M1
Gerber, D1
Dietrich, D1
Caspar, CB1
Mingrone, W1
Beretta, K1
Strasser, F1
Ruhstaller, T1
Mora, O1
Herrmann, R1
Shibata, T1
Kokubu, A1
Gotoh, M1
Ojima, H1
Ohta, T1
Yamamoto, M1
Hirohashi, S1
Kim, K1
Chie, EK1
Jang, JY1
Kim, SW1
Oh, DY3
Im, SA3
Kim, TY3
Bang, YJ3
Ha, SW1
Kim, MJ1
Lee, SH1
Kim, DW1
Heo, DS1
Berglund, A1
Byström, P1
Johansson, B1
Nygren, P1
Frödin, JE1
Pedersen, D1
Letocha, H1
Glimelius, B3
Pino, MS1
Milella, M1
Gelibter, A1
Sperduti, I1
De Marco, S1
Nuzzo, C1
Bria, E1
Carpanese, L1
Ruggeri, EM1
Carlini, P1
Cognetti, F1
Kim, BG1
Kwon, HC2
Kim, SH1
Kim, YH2
Rho, MS1
Jeong, JS1
Kim, HJ2
Pacetti, P2
Giovannetti, E1
Mambrini, A4
Nannizzi, S1
Orlandi, M2
Tartarini, R1
Del Freo, A2
Del Tacca, M1
Danesi, R1
Cantore, M4
Chen, JS4
Chao, Y1
Yang, TS1
Chou, WC1
Chen, LT1
Lee, KD1
Lin, YC3
Recchia, F1
Sica, G1
Candeloro, G1
Bisegna, R1
Bratta, M1
Bonfili, P1
Necozione, S1
Tombolini, V1
Rea, S1
Shimoda, M1
Sawada, T1
Kubota, K1
Wolf, S1
Lorenz, J1
Mössner, J3
Wiedmann, M3
Cereda, S1
Passoni, P1
Reni, M1
Viganò, MG1
Nicoletti, R1
Villa, E1
Jeong, CY1
Hong, SC1
Ha, CY1
Lee, GW1
Kang, JH1
Cassier, PA1
Thevenet, C1
Walter, T1
Baulieux, J1
Scoazec, JY1
Bancel, B1
Adham, M1
Souquet, JC1
Ponchon, T1
Lombard-Bohas, C1
Gunnlaugsson, A1
Anderson, H1
Lind, P1
Johnsson, A1
Muneoka, K1
Shirai, Y1
Sasaki, M2
Wakai, T1
Sakata, J1
Kanda, J1
Wakabayashi, H1
Hatakeyama, K1
Ko, AH1
Espinoza, AM1
Jones, KA1
Venook, AP1
Bergsland, EK1
Kelley, RK1
Dito, E1
Ong, A1
Hanover, CS1
Coakley, FV1
Tempero, MA1
Kawashima, R1
Abei, M1
Fukuda, K1
Nakamura, K1
Murata, T1
Wakayama, M1
Seo, E1
Hasegawa, N1
Mizuguchi, H1
Obata, Y1
Hyodo, I1
Hamada, H1
Yokoyama, KK1
Hayashi, T1
Ishiwatari, H1
Yoshida, M1
Sato, T3
Miyanishi, K1
Sato, Y3
Kobune, M1
Takimoto, R1
Sonoda, T1
Kato, J1
Konishi, M1
Santini, D1
Virzi, V1
Vasile, E1
Vincenzi, B1
Catalano, V1
Graziano, F1
Masi, G1
Bronte, G1
Russo, A1
Falcone, A1
Tonini, G1
Jensen, LH1
Lindebjerg, J1
Ploen, J1
Hansen, TF1
Jakobsen, A1
Hashimoto, A1
Nishiofuku, H1
Tanaka, T1
Sho, M1
Anai, H1
Nakajima, Y1
Kichikawa, K1
Furuse, J2
Kasuga, A1
Takasu, A1
Kitamura, H1
Nagashima, F1
Lim, KH1
Han, SW1
Novarino, AM1
Satolli, MA1
Chiappino, I2
Giacobino, A1
Napoletano, R1
Ceccarelli, M1
Ciccone, G1
Schena, M1
Bertetto, O1
Ciuffreda, L1
Kim, HB1
Park, JW1
Kim, CM1
Bischoff, S1
Nehls, O3
Pelzer, U1
von Weizsäcker, F1
Kubicka, S1
Stieler, JM1
Caca, K3
LoConte, NK1
Holen, KD1
Schelman, WR1
Mulkerin, DL1
Deming, DA1
Hernan, HR1
Traynor, AM1
Goggins, T1
Groteluschen, D1
Oettel, K1
Robinson, E1
Lubner, SJ1
Sasaki, T1
Isayama, H1
Nakai, Y1
Takahara, N1
Sasahira, N1
Kogure, H2
Mizuno, S1
Yagioka, H1
Ito, Y1
Yamamoto, N1
Hirano, K1
Toda, N1
Tada, M1
Omata, M1
Koike, K1
Taïeb, J1
Mitry, E1
Boige, V1
Artru, P1
Ezenfis, J1
Clavero-Fabri, MC2
Vaillant, JN1
Rougier, P3
Ducreux, M3
Klump, B2
Arkenau, HT1
Hass, HG2
Greschniok, A1
Gregor, M2
Porschen, R1
Kliche, KO1
Kubsch, K1
Raida, M1
Masri-Zada, R1
Höffken, K1
Boxberger, F1
Jüngert, B1
Brueckl, V1
Brueckl, WM1
Hautmann, M1
Hohenberger, W1
Hahn, EG1
Wein, A1
Okusaka, T4
Murad, AM1
Guimarães, RC1
Aragão, BC1
Rodrigues, VH1
Scalabrini-Neto, AO1
Padua, CA1
Moore, FC1
Morizane, C2
Okada, S3
Ueno, H2
Saisho, T1
WEISS, AJ1
JACKSON, L1
Kreth, F1
Feisthammel, J2
Deininger, M1
Kornek, GV2
Schuell, B1
Laengle, F1
Gruenberger, T1
Penz, M1
Karall, K1
Depisch, D1
Lang, F2
Scheithauer, W2
Hsu, C1
Shen, YC1
Yang, CH1
Yeh, KH1
Lu, YS1
Hsu, CH1
Liu, HT1
Li, CC1
Wu, CY1
Cheng, AL1
Enjoji, M1
Yamaguchi, K1
Nakamuta, M1
Nakashima, M1
Kotoh, K1
Tanaka, M1
Nawata, H1
Watanabe, T1
Takeda, Y1
Hasuike, Y1
Kashiwazaki, M1
Tsujinaka, T1
Alberts, SR1
Al-Khatib, H1
Mahoney, MR1
Burgart, L1
Cera, PJ1
Flynn, PJ1
Finch, TR1
Levitt, R1
Windschitl, HE1
Knost, JA1
Tschetter, LK1
Van Cutsem, E1
Van Laethem, JL2
Gress, TM1
Jeziorski, K1
Wagener, T1
Anak, O1
Baron, B1
Nordlinger, B1
Fiorentini, G3
Rabbi, C2
Zamagni, D2
Caudana, R2
Pennucci, C1
Sanguinetti, F1
Lombardi, M1
Nicoli, N1
Rao, S1
Cunningham, D3
Hawkins, RE1
Hill, ME1
Smith, D1
Daniel, F1
Ross, PJ2
Oates, J2
Norman, AR2
Chang, YS1
Yu, JS1
Uchida, S1
Nokita, H1
Horiuchi, H1
Hisaka, T1
Ishikawa, H1
Kawashima, Y1
Fujishita, M1
Kinoshita, H2
Aoyagi, S1
Shirouzu, K1
Park, SH1
Park, YH1
Lee, JN1
Cho, EK1
Shin, DB1
Nakamura, N1
Teramoto, K1
Arii, S1
Ikeda, M1
Czito, BG1
Hong, TJ1
Cohen, DP1
Petros, WP1
Tyler, DS1
Pappas, TN1
Yu, D1
Lee, CG1
Lockhart, AC1
Morse, MA1
Fernando, N1
Hurwitz, HI1
de Aretxabala, X1
Roa, I1
Berrios, M1
Hepp, J1
Gallardo, J1
Cordova, A1
Roa, JC1
Leon, J1
Maluenda, F1
Carlone, N1
Manni, A1
Torri, T2
Sato, K1
Kitajima, Y1
Miyoshi, A1
Koga, Y1
Miyazaki, K1
Iyama, S1
Takahashi, Y1
Shintani, N1
Fujikawa, K1
Ohkubo, S1
Ohnuma, K1
Niitsu, Y1
Hong, YS1
Lee, J1
Lee, SC1
Choi, SH1
Heo, JS1
Lim, HY1
Kang, WK1
Ciuleanu, T1
Diculescu, M1
Hoepffner, NM1
Trojan, J2
Sailer, V1
Zalupski, M1
Herrmann, T1
Roth, A1
Chick, J1
Brock, K1
Albert, D1
Philip, PA1
Schoppmeyer, K1
Schulze, M1
Riechelmann, RP1
Townsley, CA1
Chin, SN1
Pond, GR1
Knox, JJ1
Blanchard, P1
Huguet, F1
André, T1
Harder, J1
Kummer, O1
Olschewski, M1
Otto, F1
Blum, HE1
Opitz, O1
Yonemoto, N1
Yamao, K1
Funakoshi, A1
Ohkawa, S1
Boku, N1
Tanaka, K1
Nagase, M1
Saisho, H1
Oettle, H1
Hartmann, JT1
Hofheinz, RD1
Horger, MS1
Koppenhöfer, U1
Hochhaus, A1
Stieler, J1
Hezel, AF1
Harvey, JH1
Smith, FP1
Schein, PS1
Bedikian, AY1
Valdivieso, M2
Bodey, GP2
Ellis, PA1
Norman, A1
Hill, A1
O'Brien, ME1
Nicolson, M1
Hickish, T1
Curley, SA2
Akaishi, S1
Kobari, M1
Yusa, T1
Yamanami, H1
Furukawa, T1
Matsuno, S1
Kajanti, M1
Pyrhönen, S2
Stevens, HP1
Ostlere, LS1
Begent, RH1
Dooley, JS1
Rustin, MH1
Vaughn, DJ1
Treat, J1
Takada, T3
Kato, H2
Matsushiro, T2
Nimura, Y1
Nagakawa, T1
Nakayama, T1
Yamauchi, H2
Ogata, Y1
Shimada, H1
Miyakawa, S1
Sakoda, K1
Yasuda, H2
Tsukada, K1
Yoshida, K2
Ashida, H1
Ishikawa, Y1
Kotoura, Y1
Kajiwara, T1
Watanabe, G2
Uchimura, M1
Funabiki, T1
Ikeda, S1
Patt, YZ2
Jones, DV1
Hoque, A1
Lozano, R1
Markowitz, A1
Raijman, I2
Lynch, P1
Charnsangavej, C1
Hoffman, K1
Sjödén, PO1
Jacobsson, G1
Sellström, H1
Enander, LK1
Linné, T1
Svensson, C1
Polyzos, A1
Nikou, G1
Giannopoulos, A1
Toskas, A1
Kalahanis, N1
Papargyriou, J1
Michail, P1
Papachristodoulou, A1
Webb, A1
Prendiville, J1
Jan, YY2
Wang, HM1
Chang, WC1
Liau, CT2
Fandi, A1
Villing, AL1
Fassone, F1
Fandi, L1
Zarba, J1
Armand, JP1
Hedayati, B1
Burke, D1
Shousha, S1
Allen-Mersh, TG1
Moon, Y2
Todoroki, T2
Ohno, T2
Fukao, K2
Little, JB2
Raderer, M1
Hejna, MH1
Valencak, JB1
Weinländer, GS1
Bareck, E1
Lenauer, J1
Brodowicz, T1
van Groeningen, CJ1
Higashi, S1
Kato, C1
Sakumoto, H1
Sumiyoshi, K1
Takahahsi, T1
Matsumoto, K1
Kane, T1
Sakoda, M1
Takahashi, M1
Hosono, Y1
Asano, M1
Yamamoto, A1
Eckel, F1
Lersch, C1
Assmann, G1
Schulte-Frohlinde, E1
Zanon, C1
Alabiso, O1
Grosso, M1
Buosi, R1
Clara, R1
Satolli, A1
Zai, S1
Bortolini, M1
Botta, M1
Mussa, A1
Choi, CW1
Choi, IK1
Seo, JH1
Kim, BS1
Kim, CD1
Um, SH1
Caroli-Bosc, FX1
Gay, F1
Hendlisz, A1
Forget, F1
Bleiberg, H1
Habara, K1
Ajiki, T1
Kamigaki, T1
Nakamura, T1
Kuroda, Y1
Stevenson, JP1
O'Dwyer, PJ1
Hassan, MM1
Lozano, RD1
Waugh, KA1
Hoque, AM1
Frome, AI1
Lahoti, S1
Ellis, L1
Vauthey, JN1
Schnirer, II1
Hall, SW1
Benjamin, RS1
Murphy, WK1
Kajihara, T1
Hanaue, H1
Shimizu, T1
Yamazaki, S1
Goseki, N1
Endo, M1
Minsky, BD1
Kemeny, N1
Armstrong, JG1
Reichman, B1
Botet, J1
Valtonen, M1
Abad, A1
Rosell, R1
Barnadas, A1
Carles, J1
Ribelles, N1
Solano, V1
Okazaki, N1
Tomita, T1
Tajima, T1
Ishibashi, M1
Tagaya, N1
Aoki, H1
Itoh, S1
Kadowaki, A1
Tajima, Y1
Order, SE1
Klein, JL1
Leichner, PK1
Ettinger, DS1
Kopher, K1
Finney, K1
Surdyke, M1
Leibel, SA1
Uchiyama, K1
Hasegawa, H1

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours[NCT02591030]Phase 2/Phase 3191 participants (Actual)Interventional2015-12-15Completed
Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma[NCT02456714]Phase 230 participants (Actual)Interventional2016-05-31Completed
A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin[NCT03464968]Phase 2120 participants (Actual)Interventional2015-07-29Completed
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681]Phase 26 participants (Actual)Interventional2014-09-30Terminated (stopped due to lack of funding)
Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508]Phase 2178 participants (Actual)Interventional2018-09-04Completed
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069]Phase 127 participants (Actual)Interventional2012-04-03Terminated (stopped due to Equipment that was used in the study was discontinued)
Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905]Phase 244 participants (Actual)Interventional2003-04-30Completed
Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399]Phase 3172 participants (Anticipated)Interventional2009-09-30Completed
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma[NCT00779454]Phase 272 participants (Actual)Interventional2008-09-30Completed
Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893]Phase 242 participants (Actual)Interventional2001-05-31Completed
Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195]Phase 3286 participants (Anticipated)Interventional2015-07-31Recruiting
Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746]Phase 1/Phase 25 participants (Actual)Interventional2011-10-31Terminated (stopped due to Not enough inclusion)
International Registry on Cholangiocarcinoma Treatment[NCT01920503]40 participants (Anticipated)Observational [Patient Registry]2013-07-31Recruiting
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703]Phase 238 participants (Actual)Interventional2005-08-31Completed
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802]190 participants (Anticipated)Observational2016-10-06Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment6

Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment1

Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy

InterventionParticipants (Count of Participants)
Treatment1

Reviews

22 reviews available for fluorouracil and Biliary Tract Cancer

ArticleYear
Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2020, Volume: 22, Issue:7

    Topics: Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, Local; R

2020
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
    Oncology research and treatment, 2020, Volume: 43, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2020
Biliary cancer: gateway to comprehensive molecular profiling.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplat

2021
The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bilia

2022
[Chemotherapy for Biliary Tract Cancer].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2017, Mar-25, Volume: 69, Issue:3

    Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycyt

2017
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
    Journal of cellular physiology, 2019, Volume: 234, Issue:6

    Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemci

2019
Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:7

    Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Deoxycytidine

2014
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuv

2012
Role of chemotherapy in treatments for biliary tract cancer.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:4

    Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisp

2012
Chemotherapy for biliary tract cancer in Japan.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2002
[Systemic chemotherapy with gemcitabine for advanced biliary tract carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract

2006
[5 -fluoropyrimidines for treatment of biliary tract cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cape

2006
Chemoradiotherapy in gallbladder cancer.
    Journal of surgical oncology, 2006, Jun-15, Volume: 93, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2006
[A case of recurrent biliary cystadenocarcinoma successfully treated with 5FU/CDDP systemic chemotherapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2006, Volume: 103, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cystadenocarcino

2006
[Gemcitabine and digestive carcinomas].
    Bulletin du cancer, 2007, Volume: 94 Spec No Actualites

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2007
Systemic therapy for biliary tract cancers.
    The oncologist, 2008, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycy

2008
Systemic chemotherapy for advanced gastrointestinal cancer.
    Southern medical journal, 1980, Volume: 73, Issue:8

    Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio

1980
Update on regional treatments for hepatobiliary malignancies.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular;

1995
Cancers of the large bowel and hepatobiliary tract.
    Cancer chemotherapy and biological response modifiers, 1996, Volume: 16

    Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as

1996
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic;

1996
Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10 Suppl 4

    Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Inf

1999
Cancers of the large bowel and hepatobiliary tract.
    Cancer chemotherapy and biological response modifiers, 2001, Volume: 19

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2001

Trials

62 trials available for fluorouracil and Biliary Tract Cancer

ArticleYear
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-20, Volume: 40, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid

2022
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
    British journal of cancer, 2020, Volume: 122, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deo

2020
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 130

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Female; Fluor

2020
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 154

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; De

2021
Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study.
    Digestive diseases and sciences, 2013, Volume: 58, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Drug Administration Schedule; Drug Ther

2013
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoco

2013
Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid

2014
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine;

2015
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    American journal of clinical oncology, 2018, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2018
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
    Anti-cancer drugs, 2008, Volume: 19, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Fluoro

2008
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine;

2008
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bilia

2008
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2010
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
    Oncology, 2009, Volume: 76, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2009
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2009
A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucorvin for advanced biliary tract carcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2009
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
    Pancreas, 2009, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabin

2009
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dos

2011
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 95, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2010
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    American journal of clinical oncology, 2012, Volume: 35, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine;

2012
A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer.
    International journal of clinical oncology, 2012, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Co

2012
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
    Oncology, 2012, Volume: 82, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Oncology, 2012, Volume: 83, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Diseas

2012
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    American journal of clinical oncology, 2013, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo

2013
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2013
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2002
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.
    British journal of cancer, 2002, Sep-23, Volume: 87, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2002
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne

2002
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2003
Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dru

2003
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo

2004
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
    British journal of cancer, 2004, May-04, Volume: 90, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar

2004
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress

2005
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress

2005
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress

2005
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Disease Progress

2005
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
    British journal of cancer, 2005, May-09, Volume: 92, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Etoposide; Fem

2005
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cancer, 2005, Dec-15, Volume: 104, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle

2005
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
    Cancer, 2006, Jan-15, Volume: 106, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2006
A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
    Cancer investigation, 2006, Volume: 24, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Combined Modality The

2006
Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary

2003
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine;

2007
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
    Investigational new drugs, 2007, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract

2007
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.
    American journal of clinical oncology, 2007, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Camptothecin; Female; F

2007
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
    Cancer, 2007, Sep-15, Volume: 110, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2007
Intra-arterial and systemic chemotherapy plus external hyperthermia in unresectable biliary cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2007, Volume: 19, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine;

2007
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
    British journal of cancer, 2008, Jan-29, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2008
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hep

1995
Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi

1994
[Prospective randomized trial comparing 1/2 FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Stu
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxorubicin; F

1996
Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neop

1996
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Etoposide; Fem

1996
Chemotherapy of biliary tract cancer with mitomycin-C and 5-fluorouracil biologically modulated by folinic acid. A phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Drug Administration S

1996
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
    Anti-cancer drugs, 1998, Volume: 9, Issue:5

    Topics: Aged; Anorexia; Antidotes; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Bone Marrow; Di

1998
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cis

1998
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
    Oncology, 1999, Volume: 56, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C

1999
[Arterial infusion therapy with implantable port for inoperable hepatobiliary tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

1999
Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cyclophosphami

2000
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
    American journal of clinical oncology, 2000, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2000
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia

2001
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Dig

2001
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2001
[Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group o
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy,

1992

Other Studies

62 other studies available for fluorouracil and Biliary Tract Cancer

ArticleYear
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer.
    The Lancet. Oncology, 2022, Volume: 23, Issue:1

    Topics: Biliary Tract Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin

2022
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.
    The Lancet. Oncology, 2022, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Fluorouracil; Humans; Irino

2022
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
    Cancer medicine, 2023, Volume: 12, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic

2023
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capeci

2023
[Biliary tract cancer: on the way to a personalized therapy].
    Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisp

2020
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
    BMC cancer, 2020, Jun-03, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2020
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidi

2020
Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.
    Annals of surgical oncology, 2020, Volume: 27, Issue:13

    Topics: Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Fluorouracil; Humans; Retrospe

2020
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:5

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Che

2021
Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer.
    Tumori, 2017, Jul-31, Volume: 103, Issue:4

    Topics: Adult; Aged; Biliary Tract Neoplasms; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Fema

2017
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
    Anti-cancer drugs, 2013, Volume: 24, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2013
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
    BMC cancer, 2013, Oct-16, Volume: 13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tr

2013
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy

2014
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2013
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Deoxycytidine; Fe

2014
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Chemotherapy, 2013, Volume: 59, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabi

2013
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2014
The Influence of Aging on Hepatic Regeneration and Early Outcome after Portal Vein Occlusion: A Case-Control Study.
    Annals of surgical oncology, 2015, Volume: 22, Issue:12

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols;

2015
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
    Anti-cancer drugs, 2015, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahep

2015
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms;

2015
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
    British journal of cancer, 2017, Feb-28, Volume: 116, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2017
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
    Gastroenterology, 2008, Volume: 135, Issue:4

    Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; DNA, Complementary; Down

2008
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:2

    Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F

2009
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    BMC cancer, 2008, Dec-18, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2008
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
    Anticancer research, 2009, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2009
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers.
    Pathobiology : journal of immunopathology, molecular and cellular biology, 2009, Volume: 76, Issue:4

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Dihydrouracil Dehydro

2009
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
    World journal of gastroenterology, 2010, Jan-14, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine;

2010
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
    Cancer, 2010, May-01, Volume: 116, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2010
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2010
[Effect of pylorus-preserving pancreaticoduodenectomy on serum levels of 5-fluorouracil during S-1 treatment for pancreaticobiliary malignancy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Drug Combinations; Female; Fluoroura

2010
EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
    International journal of cancer, 2011, Sep-01, Volume: 129, Issue:5

    Topics: Adenocarcinoma; Adenoviridae; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites,

2011
Safety and optimal management of hepatic arterial infusion chemotherapy after pancreatectomy for pancreatobiliary cancer.
    AJR. American journal of roentgenology, 2012, Volume: 198, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Biliary Tract Neoplasms; Chi-Squar

2012
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Chemotherapy, 2012, Volume: 58, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bi

2012
Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.
    Onkologie, 2012, Volume: 35, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2012
Improvement of prognosis for unresectable biliary tract cancer.
    World journal of gastroenterology, 2013, Jan-07, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disea

2013
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
    Anti-cancer drugs, 2003, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxy

2003
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
    The American journal of gastroenterology, 1961, Volume: 35

    Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T

1961
Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?
    Anti-cancer drugs, 2003, Volume: 14, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biliary Tract Neoplasms; Cell Division; Cell Line, Tum

2003
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:9

    Topics: Antigens, Neoplasm; Bile Ducts, Extrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 An

2004
[Adjuvant arterial infusion chemotherapy for patients with biliary cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chem

2004
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola

2005
[The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Aged; Alprostadil; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols;

2005
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment.
    International journal of oncology, 2006, Volume: 29, Issue:2

    Topics: Antimetabolites, Antineoplastic; Base Sequence; Biliary Tract Neoplasms; Cell Line, Tumor; Enzyme In

2006
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2007
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisp

2007
5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:11

    Topics: Adenoma, Bile Duct; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

1984
[Transfer of carmofur (HCFU) to the serum, bile, pancreatic juice and pancreatic tumor tissue in the cases of peri-pancreatic head cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:5

    Topics: Administration, Oral; Antineoplastic Agents; Bile; Biliary Tract Neoplasms; Fluorouracil; Humans; Pa

1995
Pellagra secondary to 5-fluorouracil.
    The British journal of dermatology, 1993, Volume: 128, Issue:5

    Topics: Aged; Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Male; Nicotinic Acids; Pellagr

1993
A cystic biliary tumour responding to regional fluorinated pyrimidine infusion.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1998, Volume: 24, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract

1998
Killing effects of 5-fluorouracil on human biliary tract cancer cell lines.
    International journal of oncology, 1999, Volume: 14, Issue:2

    Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Death; Cell Division; Dose-Response R

1999
Enhanced radiation killing by 5-fluorouracil of biliary tract cancer cell lines.
    International journal of oncology, 2000, Volume: 16, Issue:5

    Topics: Biliary Tract Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Lethal Dose 50; Radiation

2000
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 2000, Volume: 27, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil;

2000
High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.
    Japanese journal of cancer research : Gann, 2001, Volume: 92, Issue:10

    Topics: Biliary Tract Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relati

2001
Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer.
    Cancer, 1979, Volume: 44, Issue:6

    Topics: Adult; Aged; Biliary Tract Neoplasms; Bone Marrow; Carmustine; Doxorubicin; Drug Therapy, Combinatio

1979
[Nutritional therapy of patient with advanced biliary tract cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 1991, Volume: 49 Suppl

    Topics: Biliary Tract Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Mitom

1991
Extrahepatic biliary system cancer: an update of a combined modality approach.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Brach

1991
Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
    Lancet (London, England), 1990, Jul-14, Volume: 336, Issue:8707

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxo

1990
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili

1991
[Chemotherapy in cancers of the gallbladder and bile ducts].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cytarabine;

1991
[Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile; Biliary Tract Neoplasms; Cholestasis; Fe

1989
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1986, Volume: 100

    Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C

1986
[Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:5

    Topics: Biliary Tract Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Lymph Nodes; Pancreatic Neoplasms; P

1985
chemdatabank.com